COVID-19

Investigators in California are conducting FDA-approved, double-blind, placebo-controlled phase 1 trials of traditional Eastern medicines to determine the safety and efficacy in mild-to-moderate cases of COVID-19.

Sunir J. Garg, MD, speaks on the influence of COVID-19 universal face masking on the risk of endophthalmitis following intravitreal anti-VEGF injections.

According to a team of investigators in Israel, after a third dose of the Pfizer-BioNTech COVID-19 vaccine, the antibody titers increased significantly in individuals over the age of 60.

Perspectives from a pediatric ophthalmologist and mother.

According to investigators, the SARS-CoV-2 spike protein physically interacts with GRP78 on the cell surface in patients with diabetes and promotes the binding to and accumulation in angiotensin-converting enzyme 2 (ACE2)-expressing cells.

A team of investigators from the University of Michigan may have unlocked a potential new recipe for counteracting the impact that COVID-19 has on patients with underlying disease processes such as type 2 diabetes.

The study investigated rates of cognitive impairment among survivors of COVID-19 who had been treated in outpatient, emergency department, or inpatient hospital settings.

According to a team of French investigators, every patient hospitalized with severe COVID-19 cases in their study had retinal and choroidal anomalies on indocyanine green angiography and optical coherence tomography images that were possibly related to the virus.

All of the newborns in a recent study had ocular manifestations, the most common being periorbital edema and hemorrhagic conjunctivitis,

The Delta variant still predominates in the US and UK, but the CDC mentions the AY variants as a concern, and suggested that it may be more contagious and more severe than the original COVID-19 strain.

A team of Israeli investigators sought to characterize breakthrough cases by evaluating health care workers with COVID-19 symptoms or who had been exposed to the virus.

The FDA will decide whether to authorize the boosters based off the advisory panel's recommendations.

A team of investigators at Cleveland Clinic Abu Dhabi studied patients who presented with ocular adverse events within 15 days after the first of 2 doses of the inactivated COVID-19 vaccine Sinopharm.

Investigators find that long-term ocular complications require further observation.

A simple solution that involves use of air filtration devices may help reduce the risk of hospital-acquired SARS-CoV-2 infections.

Merck and Ridgeback Biotherapeutics are seeking emergency use authorization for molnupiravir, an oral experimental antiviral treatment for mild-to-moderate COVID-19 in adults at risk for virus progression or hospitalization.

Investigators in the United Kingdom found that concomitant vaccination of flu and COVID-19 raised no safety concerns and preserved the immune response to both vaccines.

According to investigators, the BNT162b2 (Pfizer–BioNTech) vaccine appears to be highly effective in preventing hospital admissions for up to about 6 months after vaccine recipients are fully vaccinated

Pfizer’s study will evaluate the investigational novel oral antiviral candidate PF-07321332 for the prevention of illness in adults living in the same household as someone with COVID-19.

Stanford University researchers released information indicating that in hospitalized patients with severe COVID-19, the virus can cause production of autoantibodies that can, in effect, cause the body to attack itself and result in inflammatory diseases.

Massachusetts researchers are reporting structural disparities in vaccine distribution in the state.

Researchers conducting a case-control surveillance of COVID-19 vaccination during pregnancy found that spontaneous abortions did not increase as a result of vaccinations.

Investigators are working on the development of an intranasal subunit vaccine that provides durable local immunity against inhaled pathogens.

The organization’s policies come amid federal mandates designed to spur Americans who are not vaccinated against COVID-19 to get a shot.

Researchers found that the effectiveness of the vaccine held for about 6 months in most adults, but began to be less effective at that time point.